Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases

Chiara Trevisiol, F. Di Fabio, R. Nascimbeni, L. Peloso, C. Salbe, E. Ferruzzi, B. Salerni, M. Gion

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

While tissue KRAS2 mutations have been extensively investigated, the role of circulating mutant KRAS2 gene in patients with colorectal carcinoma remains obscure. The aim of the present study was to explore the prognostic significance of circulating KRAS2 gene mutational status in subjects undergoing primary treatment for colorectal cancer. Codon 12 KRAS2 mutations were examined in DNA samples extracted from the serum of 86 patients with colorectal cancer and were compared with the KRAS2 status of their primary tumors. Tissue and serum KRAS2 status was compared with other clinicopathological variables (including CEA and CA 19-9 levels) and with cancer-related survival. KRAS2 mutations were found in tissue samples of 28 patients (33%); serum KRAS2 mutations were detected in 10 of them (36%). Serum KRAS2 status was significantly associated with Dukes' stage D (p=0.001) and with preoperative CA 19-9 levels (p=0.01). At multivariate analysis, cancer-related survival was associated with Dukes' stage (p

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalInternational Journal of Biological Markers
Volume21
Issue number4
Publication statusPublished - Oct 2006

Fingerprint

Colorectal Neoplasms
Genes
Tissue
Neoplasm Metastasis
Mutation
Serum
Neoplasms
Survival
Tumors
Codon
Multivariate Analysis
DNA
Therapeutics

Keywords

  • Biological markers
  • Colorectal neoplasms
  • Genes
  • Prognosis
  • Ras
  • Serum

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Trevisiol, C., Di Fabio, F., Nascimbeni, R., Peloso, L., Salbe, C., Ferruzzi, E., ... Gion, M. (2006). Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. International Journal of Biological Markers, 21(4), 223-228.

Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. / Trevisiol, Chiara; Di Fabio, F.; Nascimbeni, R.; Peloso, L.; Salbe, C.; Ferruzzi, E.; Salerni, B.; Gion, M.

In: International Journal of Biological Markers, Vol. 21, No. 4, 10.2006, p. 223-228.

Research output: Contribution to journalArticle

Trevisiol, C, Di Fabio, F, Nascimbeni, R, Peloso, L, Salbe, C, Ferruzzi, E, Salerni, B & Gion, M 2006, 'Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases', International Journal of Biological Markers, vol. 21, no. 4, pp. 223-228.
Trevisiol C, Di Fabio F, Nascimbeni R, Peloso L, Salbe C, Ferruzzi E et al. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. International Journal of Biological Markers. 2006 Oct;21(4):223-228.
Trevisiol, Chiara ; Di Fabio, F. ; Nascimbeni, R. ; Peloso, L. ; Salbe, C. ; Ferruzzi, E. ; Salerni, B. ; Gion, M. / Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. In: International Journal of Biological Markers. 2006 ; Vol. 21, No. 4. pp. 223-228.
@article{bec0b382b69e4b9d9dfd23d3e17af3f1,
title = "Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases",
abstract = "While tissue KRAS2 mutations have been extensively investigated, the role of circulating mutant KRAS2 gene in patients with colorectal carcinoma remains obscure. The aim of the present study was to explore the prognostic significance of circulating KRAS2 gene mutational status in subjects undergoing primary treatment for colorectal cancer. Codon 12 KRAS2 mutations were examined in DNA samples extracted from the serum of 86 patients with colorectal cancer and were compared with the KRAS2 status of their primary tumors. Tissue and serum KRAS2 status was compared with other clinicopathological variables (including CEA and CA 19-9 levels) and with cancer-related survival. KRAS2 mutations were found in tissue samples of 28 patients (33{\%}); serum KRAS2 mutations were detected in 10 of them (36{\%}). Serum KRAS2 status was significantly associated with Dukes' stage D (p=0.001) and with preoperative CA 19-9 levels (p=0.01). At multivariate analysis, cancer-related survival was associated with Dukes' stage (p",
keywords = "Biological markers, Colorectal neoplasms, Genes, Prognosis, Ras, Serum",
author = "Chiara Trevisiol and {Di Fabio}, F. and R. Nascimbeni and L. Peloso and C. Salbe and E. Ferruzzi and B. Salerni and M. Gion",
year = "2006",
month = "10",
language = "English",
volume = "21",
pages = "223--228",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases

AU - Trevisiol, Chiara

AU - Di Fabio, F.

AU - Nascimbeni, R.

AU - Peloso, L.

AU - Salbe, C.

AU - Ferruzzi, E.

AU - Salerni, B.

AU - Gion, M.

PY - 2006/10

Y1 - 2006/10

N2 - While tissue KRAS2 mutations have been extensively investigated, the role of circulating mutant KRAS2 gene in patients with colorectal carcinoma remains obscure. The aim of the present study was to explore the prognostic significance of circulating KRAS2 gene mutational status in subjects undergoing primary treatment for colorectal cancer. Codon 12 KRAS2 mutations were examined in DNA samples extracted from the serum of 86 patients with colorectal cancer and were compared with the KRAS2 status of their primary tumors. Tissue and serum KRAS2 status was compared with other clinicopathological variables (including CEA and CA 19-9 levels) and with cancer-related survival. KRAS2 mutations were found in tissue samples of 28 patients (33%); serum KRAS2 mutations were detected in 10 of them (36%). Serum KRAS2 status was significantly associated with Dukes' stage D (p=0.001) and with preoperative CA 19-9 levels (p=0.01). At multivariate analysis, cancer-related survival was associated with Dukes' stage (p

AB - While tissue KRAS2 mutations have been extensively investigated, the role of circulating mutant KRAS2 gene in patients with colorectal carcinoma remains obscure. The aim of the present study was to explore the prognostic significance of circulating KRAS2 gene mutational status in subjects undergoing primary treatment for colorectal cancer. Codon 12 KRAS2 mutations were examined in DNA samples extracted from the serum of 86 patients with colorectal cancer and were compared with the KRAS2 status of their primary tumors. Tissue and serum KRAS2 status was compared with other clinicopathological variables (including CEA and CA 19-9 levels) and with cancer-related survival. KRAS2 mutations were found in tissue samples of 28 patients (33%); serum KRAS2 mutations were detected in 10 of them (36%). Serum KRAS2 status was significantly associated with Dukes' stage D (p=0.001) and with preoperative CA 19-9 levels (p=0.01). At multivariate analysis, cancer-related survival was associated with Dukes' stage (p

KW - Biological markers

KW - Colorectal neoplasms

KW - Genes

KW - Prognosis

KW - Ras

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=33846537534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846537534&partnerID=8YFLogxK

M3 - Article

C2 - 17177160

AN - SCOPUS:33846537534

VL - 21

SP - 223

EP - 228

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -